N-Nitroso Vonoprazan impurity peak area variation observed during drug product sample analysis by LCMS. Anyone facing same problem during the sample analysis? The initial standard solution gives stable response (%C.V. of 6 standards : below 2.0) After test sample run, the standard solution bracketing area was drastically decreased. The method was validated and sample analysis was already done in past with same validated method.
Need expert advice or suggestions.
Thanks in advance.